| MeSH term | MeSH ID | Detail |
|---|---|---|
| Edema | D004487 | 152 associated lipids |
| Precancerous Conditions | D011230 | 48 associated lipids |
| Postoperative Complications | D011183 | 5 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Surgical Wound Infection | D013530 | 7 associated lipids |
| Neoplasm Recurrence, Local | D009364 | 5 associated lipids |
| Osteonecrosis | D010020 | 5 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Heart Failure | D006333 | 36 associated lipids |
| Angioedema | D000799 | 6 associated lipids |
| Fractures, Spontaneous | D005598 | 4 associated lipids |
| Hydronephrosis | D006869 | 4 associated lipids |
| Trypanosomiasis | D014352 | 5 associated lipids |
| Alopecia | D000505 | 14 associated lipids |
| Liver Diseases | D008107 | 31 associated lipids |
| Corneal Diseases | D003316 | 13 associated lipids |
| Testicular Diseases | D013733 | 15 associated lipids |
| Facial Dermatoses | D005148 | 7 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Watanabe K et al. | Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. | 1991 | Transplant. Proc. | pmid:1703706 |
| Jorgensen WL | Rusting of the lock and key model for protein-ligand binding. | 1991 | Science | pmid:1719636 |
| Kobayashi N et al. | Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. | 1991 | Transplant. Proc. | pmid:1703707 |
| Keenan RJ et al. | Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. | 1991 | Transplantation | pmid:1719668 |
| Strasser S et al. | The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. | 1991 | Transplant. Proc. | pmid:1703709 |
| Cryan J et al. | FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1719972 |
| Ryu S and Yasunami Y | Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. | 1991 | Transplant. Proc. | pmid:1703710 |
| Karlsson H et al. | The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. | 1991 | Immunol. Lett. | pmid:1720417 |
| Alejandro R et al. | Combined liver-islet allotransplantation in man under FK 506. | 1991 | Transplant. Proc. | pmid:1703712 |
| Moochhala SM et al. | Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721277 |
| Sumpio BE and Phan S | Nephrotoxic potential of FK 506. | 1991 | Transplant. Proc. | pmid:1721278 |
| Pichard L et al. | Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. | 1991 | Transplant. Proc. | pmid:1721279 |
| Christians U et al. | Interactions of FK 506 and cyclosporine metabolism. | 1991 | Transplant. Proc. | pmid:1721280 |
| Su MS and Semerjian A | Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. | 1991 | Transplant. Proc. | pmid:1721310 |
| Andersson J et al. | The effects of FK 506 on cytokine production are dependent on the mode of cell activation. | 1991 | Transplant. Proc. | pmid:1721311 |
| Wang SC et al. | FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. | 1991 | Transplant. Proc. | pmid:1721312 |
| Woo J et al. | Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. | 1991 | Transplant. Proc. | pmid:1721313 |
| Reding R et al. | Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. | 1991 | Transplant. Proc. | pmid:1721341 |
| Uemoto S et al. | Experience with FK 506 in living related donor liver transplantation. | 1991 | Transplant. Proc. | pmid:1721342 |
| Tzakis AG et al. | FK 506 versus cyclosporine in pediatric liver transplantation. | 1991 | Transplant. Proc. | pmid:1721343 |
| Mieles LA et al. | Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. | 1991 | Transplant. Proc. | pmid:1721344 |
| Nakazato P et al. | Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. | 1991 | Transplant. Proc. | pmid:1721345 |
| Hebert MF et al. | Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721373 |
| Eiras G et al. | Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. | 1991 | Transplant. Proc. | pmid:1703357 |
| Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721374 | |
| Christians U et al. | Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. | 1991 | Transplant. Proc. | pmid:1703358 |
| Morris SM et al. | Disruption of renal function and gene expression by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721375 |
| Lagodziński Z et al. | Effect of FK 506 on B-cell responses. | 1991 | Transplant. Proc. | pmid:1703359 |
| Lieberman KV et al. | FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). | 1991 | Transplant. Proc. | pmid:1721376 |
| Demetris AJ et al. | Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703360 |
| Adams CK and Famili P | A study of the effects of the drug FK 506 on gingival tissues. | 1991 | Transplant. Proc. | pmid:1721405 |
| Pirsch JD et al. | Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721406 |
| Shinozuka H et al. | Effect of FK 506 on experimental liver carcinogenesis. | 1991 | Transplant. Proc. | pmid:1721407 |
| Pelekanou V et al. | FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. | 1991 | Transplant. Proc. | pmid:1721408 |
| Kuroki H et al. | Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. | 1991 | Transplant. Proc. | pmid:1721436 |
| Ito T et al. | Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. | 1991 | Transplant. Proc. | pmid:1721437 |
| DeValeria PA et al. | FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. | 1991 | Transplant. Proc. | pmid:1721438 |
| Jiang H et al. | Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. | 1991 | Transplant. Proc. | pmid:1721439 |
| Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. | 1991 | Hepatology | pmid:1709412 |
| Hohlfeld R | [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. | 1991 | Nervenarzt | pmid:1709725 |
| Kay JE et al. | Inhibition of T and B lymphocyte proliferation by rapamycin. | 1991 | Immunology | pmid:1709916 |
| Ringe D | Immunosuppression. Binding by design. | 1991 | Nature | pmid:1710317 |
| Lhoëst G et al. | Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. | 1991 | Pharm Acta Helv | pmid:1722046 |
| Nicoletti F et al. | FK-506 prevents diabetes in diabetes-prone BB/Wor rats. | 1991 | Int. J. Immunopharmacol. | pmid:1722192 |
| Starzl TE et al. | [Clinical experience with FK 506]. | 1991 | Presse Med | pmid:1722311 |
| Ellis D et al. | Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. | 1991 | Transplantation | pmid:1714643 |
| Granelli-Piperno A and McHugh P | Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1722332 |
| Simmons RL and Wang SC | New horizons in immunosuppression. | 1991 | Transplant. Proc. | pmid:1714645 |
| Calne RY | Immunosuppression for organ grafting. | 1991 | Transplant. Proc. | pmid:1714646 |
| Starzl TE et al. | Notes on FK 506. | 1991 | Transplant. Proc. | pmid:1714647 |